News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Should Roche (RHHBY)'s Failed Trial Give Hope To Alzheimer's Patients?


7/17/2014 6:16:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche’s Genentech unit just released a mid-stage study of a drug that seeks to slow the progression of Alzheimer’s by blocking the accumulation of a protein called amyloid beta. Like every other medicine that has attempted this approach – which remains the main one being pursued by drug companies to battle Alzheimer’s – the drug failed to yield a statistically significant benefit.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES